The U.S. House Energy and Commerce Committee voted unanimously (47-0) to advance the Give Kids a Chance Act of 2025, aiming to reinstate the Rare Pediatric Disease Priority Review Voucher (RPD PRV) program which expired in 2024. The legislation seeks to incentivize development and approval of treatments for rare pediatric conditions by providing expedited FDA review pathways. This bipartisan support signals sustained federal commitment to fostering innovation in therapies addressing critical unmet pediatric needs.